Biochemical markers of bone cell activity

AbbrName Mechanism AssaysMeanRange
NTX Aminoterminal cross-linking telopeptide of bone collagen Collagen-based Ostex (Osteomark), VITROS 27.1 nmol BCE/mmol cr 12-60
CTX Carboxyterminal cross-linking telopeptide of bone collagen Collagen-based Cross-laps (Osteometer), Elecsys 0.297 ng/mL 0.111-0.791
PYD Pyridinoline Collagen-based   
DPD Free Lysyl-pyridinoline (deoxypyridinoline) Collagen-based Metra (PyrilinksD)  
TRACP Tartrate-resistant acid phosphatase Secreted by osteoclasts    
Hyp Hydroxy-proline (not very specific) Collagen-based    

AbbrName Mechanism Assays Mean Range
Bone ALP, BAP Bone-specific alkaline phosphatase Secreted by osteoblasts Hybritech (Ostase), Metra (Alkphase-B) 10.1 ng/mL 5.8-17.5
PINP Procollagen type I N propeptide Collagen-based Incstar, Elecsys 38 ng/mL 17.3-83.4 ng/mL
PICP Procollagen type I C propeptide Collagen-based Orion, Metra (Prolagen)  
OC Osteocalcin (bone gla-protein) Secreted by osteoblasts Nichols, Cis Biointernational  
ALP Alkaline phosphatase (not very specific) Secreted by osteoblasts    

The Mean and Range in the table is from a report by Eastell, 2012 from a sample of 194 healthy Caucasian women aged 35-39. There are several different assays and the normal range is still not standardized.

If using old version of internet explorer click here

The biochemcial markers of bone formation and bone resorption are frequently called markers of "bone turnover." It is better to remember specifically which process is being measured, because sometimes the bone formation and resorption are not linked (for example, in early stages of steroid-induced osteoporosis, bone formation is low but bone resorption is high). These markers can NOT BE USED TO DIAGNOSE OSTEOPOROSIS! They help us understand the physiology of bone disease, especially in groups of patients or in clinical trials. For individual patients, the markers are of limited use and not recommended for screening or routine follow-up.

In complicated cases, or in patients who have taken bisphosphonates for a prolonged time, these tests are indicated to provide information to the physician to help decide about future therapy. Sometimes insurance companies do not pay for this test, so I have written a letter explaining why I think they help in complex patients.

Collagen Cross-links (NTX, CTX)

graph of NTX during menopause
This graph, from a paper by Sowers, shows normal women from the Study of Women's Health Across the Nation, according to the time of their menopause. The blue color is from women who had the lowest body mass index, the red had BMI from 25-30, and the green were obese women. Note that 95% of normal premenopausal women had results between 32 and 37.

What are they? As shown in the animation above, they are cross-linking molecules which are released with bone resorption and excreted by the urine.(Knott, 1998)
Measure bone resorption Calcium kinetic studies of bone formation and resorption show that the cross-links correlate highly with resorption. Also, these tests are higher in clinical situations previously known to have high bone resorption, such as Paget's disease and hyperthyroidism. (Eastell, 1997, Chavassieux, 2015, Weaver, 1997, Eriksen, 1993)
Very high levels in adolescents Levels are high in children, who have a great deal of bone resorption associated with growth and modelling of the ends of the long bones. NTX levels reach a peak at about age 14, then gradually decreases to adult values. (Bollen, 1994, Mora, 1998, Szulc, 2000)
Increased after a fracture In a prospective study, markers after a fracture were compared to those prior to the fracture. Markers were not altered in the immediate postfracture period but were clearly elevated during fracture repair, and remained elevated for up to a year after the fracture. (Ivaska, 2007)
Diurnal variation Bone resorption is highest at night, and the values of NTX or CTX are highest in the early morning. The highest and lowest values are 24% different from the mean 24-hour value. (Bollen, 1995)
Correlations with BMD are modest Correlation coefficients of NTX or CTX vs BMD in postmenopausal women vary from r = -0.3 to -0.5. These are statistically significant, but are not very useful for screening purposes. There are large errors in predicting the bone density for an individual person. (Marcus, 1999, Melton, 1997, Scariano, 2002)
Can't predict change in BMD Most studies show that a value of NTX or CTX in a postmenopausal woman is not able to predict the change in BMD over the next one to three years, unless she is taking medication for osteoporosis. One would have expected that women with higher resorption rates would lose more bone, but the current techniques for measuring both resorption rate and bone density do not show such a relationship. Even if the techniques were perfect, they might not show a predictable relationship because the rates of bone formation also influence the change in the bone density. (Marcus, 1999)
Decrease with anti-resorptive therapy Studies consistently show either NTX or CTX decrease about 40-80% with estrogen therapy or bisphosphonates. Furthermore, over 90% of patients who take the drugs have a decrease in the biochemical markers. (Ravn, 1999)
Other bone diseases NTX or CTX tests help to assess the activity of other diseases such as Paget's disease or metastatic bone lesions.(Chiu, 2015)
Predict fractures In a large prospective cohort of 7598 women older then 75, a high C-telopeptide level was associated with an increased risk of hip fracture with an odds ratio of 2.2. During the two years of study, 3% of those with a high C-telopeptide had a hip fracture. ( Garnero, 1996, Chopin, 2012. A study from Sweden found that high turnover markers were associated with fractures for up to 9 years in elderly women Ivaska, 2010).
Predict fractures with antiresorptive therapy This graph shows the relationship between the urine NTX at 3-6months and the rate of fractures in the risedronate clinical trial. The pink line is the treated group and dashed line is placebo. In general, the lower the NTX, the lower the fracture risk, expect when the NTX was very suppressed there was an increase in fracture risk (Eastell, 2007)
results of the study of risedronate in a graph

Bone formation markers

What are they? Osteoblastic activity is associated with serum osteocalcin, one of the proteins found in relatively high concentration in bone. Bone specific alkaline phosphatase (measured by radioimmunoassay, not by iso-enzyme analysis of alkaline phosphatase) is more sensitive and specific than alkaline phosphatase, this enzyme is made only by active osteoblasts. The the amino-propeptide of type I collagen (PINP) is currently the best marker of bone formation. Like many other proteins, collagen is secreted as a propeptide, and the ends are removed to synthesize collagen.
Measure bone formation These tests have been shown to correlate with bone formation as measured by bone histomorphometry or calcium kinetic studies in normal individuals. Osteocalcin appears to be more closely related to formation of osteoid than to formation of mineralized bone. Thus, in osteomalacia or disease where there is excess osteoid such as Paget's disease, the osteocalcin may be inaccurate. Osteocalcin is excreted by the kidneys, and serum values are increased in renal failure. This may occur in elderly patients with normal creatinine who have low glomerular filtration rates. Assays which measure the intact protein are less influenced by the glomerular filtration rate. Bone specific alkaline phosphatase is not influenced by renal failure (it is frequently elevated, but that is because the bone formation rate is actually high). (Weaver, 1997, Chavassieux, 2015)
Relationship to resorption In normal individuals the markers of bone formation follow the same pattern as the markers of bone resorption, because the two processes are coupled during bone remodeling. The levels are high during childhood and adolescence, low during adult years, and increase after menopause. They decrease following treatment with hormone replacement therapy or anti-resorptive drugs, but there is a lag between the decrease in the bone resorption markers and the bone formation markers.
Response to anti-resorptive therapy In the alendronate Fracture Intervention Trial, (Bauer, 2004) each standard deviation reduction in the change of bone ALP was associated with fewer spine and non-spine fractures. The effect was at least as strong as that observed with a change in the BMD after a year.
Response to other therapyOsteocalcin usually increases after treatment with 1,25-vitamin D. This may not represent increased bone formation, however, because histomorphometric studies of bone biopsies from women with osteoporosis treated with calcitriol have not shown any increase in tetracycline labelling. Fluoride causes increases in bone formation and in osteocalcin or bone alkaline phosphatase. PTH results in marked increases in these markers.
Increase with anabolic drugs The role of these markers in diagnosis or treatment of osteoporosis is still uncertain. In complex or high-risk cases they may help to define the bone physiology. But they do increase with therapy with teriparatide (the only available approved treatment of osteoporosis that is anabolic). Newer therapies still in clinical studies (such as romosozumab or abaloparatide) also increase the P1NP.

Updated 2/4/2016

link to home page link to next page